Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page
- Check2 days agoChange DetectedAdded a comprehensive Locations section listing U.S. states and Canadian provinces. Updated the page to Revision: v3.3.3 and removed the older v3.3.2 location blocks and the HHS Vulnerability Disclosure content.SummaryDifference2%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedPublications section now indicates that entries are automatically filled from PubMed and updates the revision label to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check38 days agoChange DetectedRemoved the government funding lapse notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check52 days agoChange DetectedNo significant additions or deletions were detected on the page between the two screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check81 days agoChange Detected- Updated to revision v3.2.0 and added a government operating-status notice. - Removed Mature T-cell and NK-cell non-Hodgkin lymphoma from current content.SummaryDifference3%

- Check88 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.